R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 52.75
-0.95 (-1.77%)
Sep 1, 2026, 4:00 PM EDT
R&G PharmaStudies Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 939.31 | 851.01 | 744 | 721.37 | 637.52 | 608.43 |
Revenue Growth | 26.14% | 14.38% | 3.14% | 13.15% | 4.78% | 25.59% |
Gross Profit Gross Profit Growth | 295.11 | 295.64 | 275.92 | 287.04 | 234.9 | 233.17 |
Operating Income Operating Income Growth | 123.45 | 122.51 | 121.05 | 131.11 | 102.98 | 109.15 |
Net Income Net Income Growth | 120.25 | 136.9 | 140.22 | 162.53 | 113.45 | 99.24 |
Earnings Per Share EPS Growth | 1.25 | 1.43 | 1.47 | 1.69 | 1.38 | 1.38 |
EPS Growth | -16.81% | -2.72% | -13.17% | 22.68% | -0.09% | 18.82% |
| Fiscal Year | FY 2025 | FY 2024 |
|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 |
Clinical Trial Technical Services Clinical Trial Technical Services Growth | 412.74 | 375.09 |
Clinical Trial Related and Laboratory Services Clinical Trial Related and Laboratory Services Growth | 438.27 | 368.92 |
Total Total Growth | 851.01 | 744 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 1,672 | 1,748 | 1,776 | 1,704 | 1,522 | 361.6 |
Total Debt Total Debt Growth | 42.52 | 17.87 | 71.86 | 8.86 | 15.68 | 10.98 |
Net Cash (Debt) Net Cash Growth | 1,630 | 1,730 | 1,704 | 1,695 | 1,507 | 350.62 |
Net Cash Growth | -4.39% | 1.49% | 0.56% | 12.50% | 329.70% | 19.33% |
Net Cash Per Share Net Cash Per Share Growth | 16.92 | 18.07 | 17.87 | 17.66 | 18.33 | 4.88 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 63.6 | 114.2 | 154.76 | 192.56 | 130.47 | 114.57 |
Capital Expenditures CapEx Growth | -17.79 | -19.28 | -19.98 | -19.88 | -20.83 | -38.28 |
Free Cash Flow Free Cash Flow Growth | 45.81 | 94.93 | 134.78 | 172.68 | 109.64 | 76.29 |
Free Cash Flow Growth | -57.49% | -29.57% | -21.95% | 57.50% | 43.71% | 309.66% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 31.42% | 34.74% | 37.09% | 39.79% | 36.85% | 38.32% |
Operating Margin | 13.14% | 14.40% | 16.27% | 18.18% | 16.15% | 17.94% |
Pretax Margin | 14.37% | 18.23% | 21.21% | 25.30% | 20.22% | 18.67% |
Profit Margin | 12.80% | 16.09% | 18.85% | 22.53% | 17.79% | 16.31% |
FCF Margin | 4.88% | 11.15% | 18.12% | 23.94% | 17.20% | 12.54% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 |
Dividend Per Share Dividend Per Share Growth | 0.160 | 0.160 | 0.160 | 0.200 | 0.156 |
Dividend Per Share Growth | 0.21% | 0% | -20.00% | 27.96% | - |
Dividend Yield | 0.25% | 0.27% | 0.32% | 0.31% | 0.31% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 42.25 | 41.39 | 33.92 | 38.09 | 43.55 | - |
Forward PE | 30.49 | 33.13 | 25.30 | 33.07 | - | - |
P/FCF Ratio | 110.53 | 59.68 | 35.29 | 35.85 | 45.06 | - |
PS Ratio | 5.39 | 6.66 | 6.39 | 8.58 | 7.75 | - |